Medscape

Botulinum Toxin Type A for Upper Limb Spasticity after Stroke

In the coming 5 years the clinical efficacy and cost–effectiveness of botulinum toxin for post-stroke upper limb spasticity will be further defined. Its role in improving active function will become ...
Nasdaq

FDA Accepts Supplemental Biologics License Applications (sBLAs) for BOTOX® (onabotulinumtoxinA) for Pediatric Patients with Upper and Lower Limb Spasticity

DUBLIN, March 7, 2019 /PRNewswire/ -- Allergan plc (NYSE:AGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental biologics license applications ...
FiercePharma

Actavis Announces FDA Approval of Expanded Label for BOTOX(R) (OnabotulinumtoxinA) for the Treatment of Upper Limb Spasticity in Adults

Label updates include addition of two thumb flexor muscles and increased maximum cumulative dose DUBLIN, April 20, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT), which recently completed the ...
The New England Journal of Medicine

Robot-Assisted Therapy for Long-Term Upper-Limb Impairment after Stroke

In this multicenter, randomized, controlled trial involving 127 patients with moderate-to-severe upper-limb impairment 6 months or more after a stroke, we randomly assigned 49 patients to receive ...
Medscape

Botulinum Toxin Type A for Upper Limb Spasticity after Stroke

Expert Rev Neurother. 2009;9(12):1713-1725. The first patients with squint were successfully treated in 1977 [17] and since then botulinum toxin type A delivered by local injection has been used in ...